As part of our series focussing on medicines in Australia, we have added a product review of the use of apremilast for psoriasis and active psoriatic arthritis.
This publication focuses on the impact of PsO and PsA along with the efficacy and safety of apremilast as a treatment. It provides commentary from a multi-disciplinary team of specialists including Clinical Associate Professor Kurt Gebauer a General Clinical Dermatologist, and Professor Paul Bird, a Rheumatologist in private practice.
Please login below to download this issue (PDF)